Johnson & Johnson Seeks to Expand Use of Psoriasis Drug


On Thursday, Johnson & Johnson (NYS: JNJ) announced that its Janssen Biotech and Janssen Biologics subsidiaries havesubmitted applications in the U.S. and Europe regarding the use of their Stelara psoriasis drug.

A supplemental Biologics License Application was submitted to the FDA and a Type II Variation was submitted to the European Medicines Agency.

The new usage will be for the treatment of adult patients with active psoriatic arthritis, a chronic, debilitating immune-mediated inflammatory disease affecting more than 2 million patients in the U.S., an estimated 4.2 million patients in Europe, and perhaps as many as 37 million people worldwide.

Johnson & Johnson noted that its twin applications are support by findings from a Phase 3 clinical trial. The company further noted that this same drug is currently in Phase 3 development for the treatment of moderately to severely active Crohn's disease.


The article Johnson & Johnson Seeks to Expand Use of Psoriasis Drug originally appeared on

Fool contributor Rich Smith has no positions in the stocks mentioned above. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.